Identifying people with diabetes at high risk of blindness and amputation:A new risk tool will help to personalise care and advice and to target resources at those in greatest need by Majeed, Azeem & Molokhia, Mariam
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1136/bmj.h5643
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Majeed, A., & Molokhia, M. (2015). Identifying people with diabetes at high risk of blindness and amputation: A
new risk tool will help to personalise care and advice and to target resources at those in greatest need. BMJ
(Clinical research ed.), 351, [h5643]. 10.1136/bmj.h5643
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Identifying people with diabetes at high risk of
blindness and amputation
A new risk tool will help to personalise care and advice and to target resources at those in greatest
need
Azeem Majeed professor of primary care 1, Mariam Molokhia clinical reader in epidemiology and
primary care 2
1Department of Primary Care and Public Health, Imperial College London, London W6 8RP, UK; 2Department of Primary Care and Public Health
Sciences, King’s College London, London SE1 3QD, UK
Blindness and lower limb amputations are among the most
feared complications of diabetes. Despite the frequency of these
complications and their effect on patients, methods of identifying
those patients with diabetes who are at greatest risk of blindness
and amputation have been lacking. This gap has now been filled
in a study by Julia Hippisley-Cox and Carol Coupland (doi:10.
1136/bmj.h5441), using data from QResearch, a large clinical
database derived from the electronic patient records used by
general practices in the United Kingdom.1
The study used data derived from electronic patient records of
around 455 000 people with diabetes from 763 general practices
in England. The same data source (QResearch) and statistical
methods used in this study have also been used to produce other
risk measurement tools—for example, QRISK, which has now
been adopted by the NHS in England for measuring the risk of
developing cardiovascular disease.2 The data from primary care
records were linked to other data sources such as NHS Hospital
Episode Statistics. The authors then used Cox proportional
hazards models to derive separate risk equations for the 10 year
risk of blindness and amputation.
The equations were subsequently validated using data from two
different sets of general practices (from QResearch and the
Clinical Practice Research Datalink). In this validation, the two
risk prediction models performed well, explaining around 41%
and 32% of the variation in time to amputation and blindness,
respectively, with good discrimination asmeasured by C statistic
values. In the final phase of their work, the authors developed
a web based calculator so that clinicians can enter their patients’
data, and patients can enter their own data, to determine the 10
year risk of these complications.3
The authors are to be congratulated on the scale of their study
and its potential impact on clinical practice and on self
management. Previous risk prediction studies in diabetes have
been on a substantially smaller scale. For example, the UK
Prospective Diabetes Study (UKPDS) was based on a sample
of around 5100 patients.4 Very few patients in the UKPDS
developed blindness (n=116) or amputation (n=45) during
follow-up, making derivation of accurate methods of predicting
these complications difficult. Data on ethnicity were also
lacking. In contrast, in the QResearch study, 4822 people had
lower limb amputations and 8063 cases of blindness occurred
during the follow-up period, and data on ethnicity were
available. The risk factors in the final models—such as age,
ethnicity, blood pressure, deprivation, glycated haemoglobin,
and smoking for the amputation risk model—are what wemight
expect on the basis of previous research on complications of
diabetes, but it is very useful to have the effect of each of these
risk factors quantified.
The scale of the morbidity from diabetes and its impact on
patients, clinicians, health systems, and societies is considerable
and growing because of the continuing increase in the global
prevalence of diabetes. Diabetic eye disease is now the second
most common cause of blindness in people of working age in
the United Kingdom and one of the most common causes of
blindness worldwide.5 6 A previous study using NHS Hospital
Episode Statistics showed increasing rates of diabetes related
amputations in England, driven largely by the rising prevalence
of type 2 diabetes.7More than 7000 diabetes related amputations
take place annually in England, which illustrates the impact of
this complication on both patients and health systems.8
The new risk prediction models can help to provide the basis
of a more individualised and holistic method of tackling these
complications in patients. People with diabetes can for the first
time be given individualised risk scores based on their own
characteristics. They can also be shown how changes in their
lifestyle or management affect their risk—for example, stopping
smoking or improving their diabetes control—thus promoting
more patient centred care for people with diabetes.9 For the
NHS, the risk prediction models will permit risk stratification
of people with diabetes, thus allowing resources to be targeted
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at those groups of people at the highest risk of complications.
This targeted use of resources is critically important in a period
when the NHS faces unprecedented financial pressures.10
Some caveats remain, however. Firstly, we need to test the
models in actual practice to see if they can improve the
management of people with diabetes and thereby lead to lower
rates of blindness and amputation. Secondly, because of the
global burden of diabetes, we also need to test the impact of the
models outside the United Kingdom, particularly in those
countries with the highest prevalence of diabetes.11
The risk prediction tools developed from QResearch are one
example of the value of the data held by the NHS in its
electronic medical records and administrative databases. These
data have great potential to improve NHS clinical care as well
as giving patients information to help them to make better
decisions about their own health. We do, however, need to
overcome the political, organisational, and technical barriers to
making greater use of these data so that the NHS, clinicians,
the public, and patients can all benefit fully from this potential.12
Imperial College London and King’s College London are grateful for
support from the NIHR Biomedical Research Centre scheme and the
NIHR Collaboration for Leadership in Applied Health Research and
Care scheme.
Competing interests: We have read and understood the BMJ policy on
declaration of interests and declare the following interests: none.
Provenance and peer review: Commissioned; not externally peer
reviewed.
1 Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to
estimate future risk of blindness and lower limb amputation in patients with diabetes:
cohort study. BMJ 2015;351:h5441.
2 Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in
England and Wales: prospective derivation and validation of QRISK2. BMJ
2008;336:1475-82.
3 ClinRisk. Welcome to the QDiabetes® (amputation and blindness)-2015 risk calculator.
qdiabetes.org/amputation-blindness/index.php.
4 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with
sulphonylureas or insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
5 Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications
in England and Wales in working age adults (16 to 64 years), 1999 to 2000 with 2009 to
2010. BMJ Open 2014;4:e004015.
6 The Eye Diseases Prevalence Research Group. Causes and prevalence of visual
impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
7 Vamos EP, Bottle A, Edmonds ME, Valabhji J, Majeed A, Millett C. Changes in the
incidence of lower extremity amputations in individuals with and without diabetes in
England between 2004 and 2008. Diabetes Care 2010;33:2592-7.
8 Diabetes UK. More than 135 diabetes amputations every week. 2015. www.diabetes.org.
uk/About_us/News/More-than-135-diabetes-amputations-every-week/.
9 Meltzer D, Egleston B. How patients with diabetes perceive their risk for major
complications. Eff Clin Pract 2000;3:7-15.
10 Ham C. The three crises facing the NHS in England. BMJ 2015;351:h5495.
11 Majeed A, El-Sayed AA, Khoja T, Alshamsan R, Millett C, Rawaf S. Diabetes in the
Middle-East and North Africa: an update. Diabetes Res Clin Pract 2014;103:218-2.
12 Majeed A. Sources, uses, strengths and limitations of data collected in primary care in
England. Health Stat Q 2004;(21):5-14.
Cite this as: BMJ 2015;351:h5643
© BMJ Publishing Group Ltd 2015
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;351:h5643 doi: 10.1136/bmj.h5643 (Published 11 November 2015) Page 2 of 2
EDITORIALS
